[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "PHARMAC staff received an application from a clinician requesting consideration for funded access to azithromycin for patients with bronchiectasis who have had at least one pulmonary infection in the last year.",
          "fs": "PHARMAC staff received an application from a clinician requesting consideration for funded access to azithromycin for patients with bronchiectasis who have had at least one pulmonary infection in the last year.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2013",
          "fs": "Nov 2013",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4i2AH"
          },
          "Id": "a0POZ00000EOA4i2AH",
          "Event_Date__c": "2013-11-01",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Summary__c": "PHARMAC staff received an application from a clinician requesting consideration for funded access to azithromycin for patients with bronchiectasis who have had at least one pulmonary infection in the last year.",
          "Formatted_Date__c": "Nov 2013",
          "Status_History__c": "a132P000000AqUGQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "July 2024: New funding application received from the New Zealand Bronchiectasis Registry, endorsed by the Thoracic Society of New Zealand NZ Branch executive and the Asthma and Respiratory Foundation NZ.",
          "fs": "July 2024: New funding application received from the New Zealand Bronchiectasis Registry, endorsed by the Thoracic Society of New Zealand NZ Branch executive and the Asthma and Respiratory Foundation NZ.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jul 2024",
          "fs": "Jul 2024",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4u2AH"
          },
          "Id": "a0POZ00000EOA4u2AH",
          "Event_Date__c": "2024-07-07",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Summary__c": "July 2024: New funding application received from the New Zealand Bronchiectasis Registry, endorsed by the Thoracic Society of New Zealand NZ Branch executive and the Asthma and Respiratory Foundation NZ.",
          "Formatted_Date__c": "Jul 2024",
          "Status_History__c": "a13OZ00000G5TWRYA3"
        },
        "change": null
      }
    ],
    "dateString": "Nov 2013",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "PHARMAC staff referred the application to the Anti-Infective Subcommittee for consideration.",
          "fs": "PHARMAC staff referred the application to the Anti-Infective Subcommittee for consideration.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2013",
          "fs": "Dec 2013",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4j2AH"
          },
          "Id": "a0POZ00000EOA4j2AH",
          "Event_Date__c": "2013-12-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Summary__c": "PHARMAC staff referred the application to the Anti-Infective Subcommittee for consideration.",
          "Formatted_Date__c": "Dec 2013",
          "Status_History__c": "a132P000000AqY2QAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "The Anti-Infective Subcommittee of PTAC deferred making a recommendation pending advice from the Respiratory Subcommittee and if available, the updated Thoracic Society of Australia and New Zealand position statement.",
          "fs": "The Anti-Infective Subcommittee of PTAC deferred making a recommendation pending advice from the Respiratory Subcommittee and if available, the updated Thoracic Society of Australia and New Zealand position statement.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Deferred",
          "fs": "Deferred",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-02.pdf\" target=\"_blank\">Anti-Infective Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-02.pdf\" target=\"_blank\">Anti-Infective Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2014",
          "fs": "Feb 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 26 February 2014.",
          "fs": "Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 26 February 2014.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4k2AH"
          },
          "Id": "a0POZ00000EOA4k2AH",
          "Event_Date__c": "2014-02-26",
          "Event_Description__c": "Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 26 February 2014.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-02.pdf\" target=\"_blank\">Anti-Infective Subcommittee minutes</a>",
          "Outcome__c": "Deferred",
          "Summary__c": "The Anti-Infective Subcommittee of PTAC deferred making a recommendation pending advice from the Respiratory Subcommittee and if available, the updated Thoracic Society of Australia and New Zealand position statement.",
          "Formatted_Date__c": "Feb 2014",
          "Status_History__c": "a132P000000AqcKQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "PHARMAC staff then referred the application to the Respiratory Subcommittee of PTAC for consideration",
          "fs": "PHARMAC staff then referred the application to the Respiratory Subcommittee of PTAC for consideration",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Mar 2014",
          "fs": "Mar 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4l2AH"
          },
          "Id": "a0POZ00000EOA4l2AH",
          "Event_Date__c": "2014-03-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Summary__c": "PHARMAC staff then referred the application to the Respiratory Subcommittee of PTAC for consideration",
          "Formatted_Date__c": "Mar 2014",
          "Status_History__c": "a132P000000AqccQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "The Respiratory Subcommittee recommended funding of azithromycin for the prevention of exacerbations in non-cystic fibrosis bronchiectasis patients who have previously had at least three exacerbations in the past 12 months with a medium priority.",
          "fs": "The Respiratory Subcommittee recommended funding of azithromycin for the prevention of exacerbations in non-cystic fibrosis bronchiectasis patients who have previously had at least three exacerbations in the past 12 months with a medium priority.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Medium",
          "fs": "Medium",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf\" target=\"_blank\">Respiratory Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf\" target=\"_blank\">Respiratory Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2014",
          "fs": "Apr 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.",
          "fs": "Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4m2AH"
          },
          "Id": "a0POZ00000EOA4m2AH",
          "Event_Date__c": "2014-04-30",
          "Event_Description__c": "Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf\" target=\"_blank\">Respiratory Subcommittee minutes</a>",
          "Outcome__c": "Medium",
          "Summary__c": "The Respiratory Subcommittee recommended funding of azithromycin for the prevention of exacerbations in non-cystic fibrosis bronchiectasis patients who have previously had at least three exacerbations in the past 12 months with a medium priority.",
          "Formatted_Date__c": "Apr 2014",
          "Status_History__c": "a132P000000AqeDQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "As requested by the Anti-Infective Subcommittee of PTAC, the minutes from the April 2014 Respiratory Subcommittee meeting along with the updated Thoracic Society of Australia and New Zealand Clinical Guidelines for Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adults in Australia and New Zealand (2014)  were referred back to the Anti-Infective Subcommittee for its consideration.",
          "fs": "As requested by the Anti-Infective Subcommittee of PTAC, the minutes from the April 2014 Respiratory Subcommittee meeting along with the updated Thoracic Society of Australia and New Zealand Clinical Guidelines for Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adults in Australia and New Zealand (2014)  were referred back to the Anti-Infective Subcommittee for its consideration.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2014",
          "fs": "May 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4n2AH"
          },
          "Id": "a0POZ00000EOA4n2AH",
          "Event_Date__c": "2014-05-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Summary__c": "As requested by the Anti-Infective Subcommittee of PTAC, the minutes from the April 2014 Respiratory Subcommittee meeting along with the updated Thoracic Society of Australia and New Zealand Clinical Guidelines for Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adults in Australia and New Zealand (2014)  were referred back to the Anti-Infective Subcommittee for its consideration.",
          "Formatted_Date__c": "May 2014",
          "Status_History__c": "a132P000000AqerQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "The Anti-Infective Subcommittee considered the application for azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis.  The Subcommittee recommended  the application for azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis in adults should be declined, noting that an alternative treatment is available for these patients.The Subcommittee recommended that longer courses of azithromycin should be restricted to non-cystic fibrosis related bronchiectasis in children who have had 3 or more exacerbations of their bronchiectasis or 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.    The application for azithromycin for bronchiectasis for non-cystic fibrosis, in children with high exacerbation or hospitalisation rates can be found as a separate item within our application tracker.",
          "fs": "The Anti-Infective Subcommittee considered the application for azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis.  The Subcommittee recommended  the application for azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis in adults should be declined, noting that an alternative treatment is available for these patients.The Subcommittee recommended that longer courses of azithromycin should be restricted to non-cystic fibrosis related bronchiectasis in children who have had 3 or more exacerbations of their bronchiectasis or 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.    The application for azithromycin for bronchiectasis for non-cystic fibrosis, in children with high exacerbation or hospitalisation rates can be found as a separate item within our application tracker.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Decline",
          "fs": "Decline",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-12-01.pdf\" target=\"_blank\">Anti-Infective Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-12-01.pdf\" target=\"_blank\">Anti-Infective Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2014",
          "fs": "Dec 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Anti-Infective Subcommittee at meeting Monday 1 December 2014.",
          "fs": "Clinical advice received from Anti-Infective Subcommittee at meeting Monday 1 December 2014.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4o2AH"
          },
          "Id": "a0POZ00000EOA4o2AH",
          "Event_Date__c": "2014-12-01",
          "Event_Description__c": "Clinical advice received from Anti-Infective Subcommittee at meeting Monday 1 December 2014.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-12-01.pdf\" target=\"_blank\">Anti-Infective Subcommittee minutes</a>",
          "Outcome__c": "Decline",
          "Summary__c": "The Anti-Infective Subcommittee considered the application for azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis.  The Subcommittee recommended  the application for azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis in adults should be declined, noting that an alternative treatment is available for these patients.The Subcommittee recommended that longer courses of azithromycin should be restricted to non-cystic fibrosis related bronchiectasis in children who have had 3 or more exacerbations of their bronchiectasis or 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.    The application for azithromycin for bronchiectasis for non-cystic fibrosis, in children with high exacerbation or hospitalisation rates can be found as a separate item within our application tracker.",
          "Formatted_Date__c": "Dec 2014",
          "Status_History__c": "a132P000000AqqHQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "Noting the variation in the recommendations between the Anti-Infective Subcommittee and the Respiratory Subcommittee, PHARMAC staff referred the application to PTAC for its deliberation.",
          "fs": "Noting the variation in the recommendations between the Anti-Infective Subcommittee and the Respiratory Subcommittee, PHARMAC staff referred the application to PTAC for its deliberation.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2015",
          "fs": "Apr 2015",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4p2AH"
          },
          "Id": "a0POZ00000EOA4p2AH",
          "Event_Date__c": "2015-04-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Summary__c": "Noting the variation in the recommendations between the Anti-Infective Subcommittee and the Respiratory Subcommittee, PHARMAC staff referred the application to PTAC for its deliberation.",
          "Formatted_Date__c": "Apr 2015",
          "Status_History__c": "a132P000000Aqu8QAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "The Committee recommended the application for azithromycin for prevention of exacerbations in adult non-cystic fibrosis bronchiectasis should be declined, noting that an alternative treatment is available for these patients.    The Committee recommended that azithromycin be funded for non-cystic fibrosis bronchiectasis in children (aged 18 or under) who have had 3 or more exacerbations of their bronchiectasis or 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period, for a maximum treatment duration of 24 months of therapy, with a high priority.  This proposal can be found as a separate item in PHARMAC&#39;s application tracker.",
          "fs": "The Committee recommended the application for azithromycin for prevention of exacerbations in adult non-cystic fibrosis bronchiectasis should be declined, noting that an alternative treatment is available for these patients.    The Committee recommended that azithromycin be funded for non-cystic fibrosis bronchiectasis in children (aged 18 or under) who have had 3 or more exacerbations of their bronchiectasis or 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period, for a maximum treatment duration of 24 months of therapy, with a high priority.  This proposal can be found as a separate item in PHARMAC&#39;s application tracker.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Decline",
          "fs": "Decline",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2015",
          "fs": "Aug 2015",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4q2AH"
          },
          "Id": "a0POZ00000EOA4q2AH",
          "Event_Date__c": "2015-08-13",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "Outcome__c": "Decline",
          "Summary__c": "The Committee recommended the application for azithromycin for prevention of exacerbations in adult non-cystic fibrosis bronchiectasis should be declined, noting that an alternative treatment is available for these patients.    The Committee recommended that azithromycin be funded for non-cystic fibrosis bronchiectasis in children (aged 18 or under) who have had 3 or more exacerbations of their bronchiectasis or 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period, for a maximum treatment duration of 24 months of therapy, with a high priority.  This proposal can be found as a separate item in PHARMAC&#39;s application tracker.",
          "Formatted_Date__c": "Aug 2015",
          "Status_History__c": "a132P000000AqyRQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "<p><span style=\"color: rgb(0, 0, 0);\">Pharmac received a new funding application in </span><span style=\"color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);\">July 2024 </span><span style=\"color: rgb(0, 0, 0);\">from the New Zealand Bronchiectasis Registry, endorsed by the Thoracic Society of New Zealand NZ Branch executive and the Asthma and Respiratory Foundation NZ.</span></p>",
          "fs": "<p><span style=\"color: rgb(0, 0, 0);\">Pharmac received a new funding application in </span><span style=\"color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);\">July 2024 </span><span style=\"color: rgb(0, 0, 0);\">from the New Zealand Bronchiectasis Registry, endorsed by the Thoracic Society of New Zealand NZ Branch executive and the Asthma and Respiratory Foundation NZ.</span></p>",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2024",
          "fs": "Nov 2024",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4w2AH"
          },
          "Id": "a0POZ00000EOA4w2AH",
          "Event_Date__c": "2024-11-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Summary__c": "<p><span style=\"color: rgb(0, 0, 0);\">Pharmac received a new funding application in </span><span style=\"color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);\">July 2024 </span><span style=\"color: rgb(0, 0, 0);\">from the New Zealand Bronchiectasis Registry, endorsed by the Thoracic Society of New Zealand NZ Branch executive and the Asthma and Respiratory Foundation NZ.</span></p>",
          "Formatted_Date__c": "Nov 2024",
          "Status_History__c": "a13OZ00000G5PsdYAF"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2013",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2015",
          "fs": "Dec 2015",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4r2AH"
          },
          "Id": "a0POZ00000EOA4r2AH",
          "Event_Date__c": "2015-12-01",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "Dec 2015",
          "Status_History__c": "a132P000000Ar3NQAS"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2015",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2\" target=\"_blank\">Consultation notification</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2\" target=\"_blank\">Consultation notification</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2023",
          "fs": "Dec 2023",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4s2AH"
          },
          "Id": "a0POZ00000EOA4s2AH",
          "Event_Date__c": "2023-12-18",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2\" target=\"_blank\">Consultation notification</a></p>",
          "Formatted_Date__c": "Dec 2023",
          "Status_History__c": "a13OZ000004kQbVYAU"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2023",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2024",
          "fs": "Feb 2024",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4t2AH"
          },
          "Id": "a0POZ00000EOA4t2AH",
          "Event_Date__c": "2024-02-12",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Formatted_Date__c": "Feb 2024",
          "Status_History__c": "a13OZ000006m6KcYAI"
        },
        "change": null
      }
    ],
    "dateString": "Feb 2024",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24\" target=\"_blank\">Decision notification</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24\" target=\"_blank\">Decision notification</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Jul 2024",
          "fs": "Jul 2024",
          "change": null
        },
        "Event_Description": {
          "s": "The funding application has been declined.",
          "fs": "The funding application has been declined.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EOA4v2AH"
          },
          "Id": "a0POZ00000EOA4v2AH",
          "Event_Date__c": "2024-07-23",
          "Event_Description__c": "The funding application has been declined.",
          "Stage__c": "Decision",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24\" target=\"_blank\">Decision notification</a></p>",
          "Formatted_Date__c": "Jul 2024",
          "Status_History__c": "a13OZ00000CTfNUYA1"
        },
        "change": null
      }
    ],
    "dateString": "Jul 2024",
    "collapsed": false,
    "checked": true
  }
]